BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12557178)

  • 1. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Van Bömmel F; Schernick A; Hopf U; Berg T
    Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou Y; Tubiana R; Thibault V
    N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
    [No Abstract]   [Full Text] [Related]  

  • 3. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
    van Bömmel F; Wünsche T; Schürmann D; Berg T
    Hepatology; 2002 Aug; 36(2):507-8. PubMed ID: 12143063
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment: a tale of two viruses.
    Dieterich DT
    AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis B infection in an HIV-positive man treated with tenofovir: a case of re-infection or reactivation?
    Richardson D; Lamba H
    Int J STD AIDS; 2004 Mar; 15(3):204-5. PubMed ID: 15038871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine for chemotherapy-induced reactivation of HBV: prophylaxis or treatment?
    Mancuso A; Pagliaro L
    Am J Gastroenterol; 2002 May; 97(5):1268-9. PubMed ID: 12014746
    [No Abstract]   [Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Jenh AM; Pham PA
    Expert Rev Anti Infect Ther; 2010 Oct; 8(10):1079-92. PubMed ID: 20954872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir helps beat hepatitis B.
    TreatmentUpdate; 2003 Jan; 15(1):4. PubMed ID: 12630369
    [No Abstract]   [Full Text] [Related]  

  • 10. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
    Mutimer D
    J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
    Matthews GV; Dore GJ
    AIDS; 2007 Mar; 21(6):777-8. PubMed ID: 17413705
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis B virus kinetics and mathematical modeling.
    Perelson AS; Ribeiro RM
    Semin Liver Dis; 2004; 24 Suppl 1():11-6. PubMed ID: 15192796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Reijnders JG; Janssen HL
    J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
    de Vries-Sluijs TE; van der Eijk AA; Hansen BE; Osterhaus AD; de Man RA; van der Ende ME
    J Clin Virol; 2006 May; 36(1):60-3. PubMed ID: 16418013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tenofovir, An antiviral agent with activity against HIV infections and hepatitis B].
    Taéron C
    Rev Infirm; 2009 Sep; (153):49-51. PubMed ID: 19771814
    [No Abstract]   [Full Text] [Related]  

  • 19. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.
    Milazzo L; Corbellino M; Foschi A; Micheli V; Dodero A; Mazzocchi A; Montefusco V; Zehender G; Antinori S
    Transpl Infect Dis; 2012 Feb; 14(1):95-8. PubMed ID: 21749588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
    Rago A; Lichtner M; Mecarocci S; Marocco R; Cenfra N; Belvisi V; Del Borgo C; Cimino G; Mastroianni CM
    Antivir Ther; 2010; 15(6):929-32. PubMed ID: 20834107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.